

PLSD Publications

1. Seppälä T, Pylvänäinen K, Evans DG, Järvinen H, Renkonen-Sinisalo L, Bernstein I, Holinski-Feder E, Sala P, Lindblom A, Macrae F, Blanco I, Sijmons R, Jeffries J, Vasen H, Burn J, Nakken S, Hovig E, Rødland EA, Tharmaratnam K, de Vos Tot Nederveen Cappel WH, Hill J, Wijnen J, Jenkins M, Genuardi M, Green K, Laloo F, Sunde L, Mints M, Bertario L, Pineda M, Navarro M, Morak M, Frayling IM, Plazzer JP, Sampson JR, Capella G, Möslein G, Mecklin JP, Møller P; Mallorca Group. Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report. *Hered Cancer Clin Pract*. 2017 Oct 10;15:18. doi: 10.1186/s13053-017-0078-5. eCollection 2017.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635542/>
2. Møller P, Seppälä TT, Bernstein I, Holinski-Feder E, Sala P, Gareth Evans D, Lindblom A, Macrae F, Blanco I, Sijmons RH, Jeffries J, Vasen HFA, Burn J, Nakken S, Hovig E, Rødland EA, Tharmaratnam K, de Vos Tot Nederveen Cappel WH, Hill J, Wijnen JT, Jenkins MA, Green K, Laloo F, Sunde L, Mints M, Bertario L, Pineda M, Navarro M, Morak M, Renkonen-Sinisalo L, Valentin MD, Frayling IM, Plazzer JP, Pylvanainen K, Genuardi M, Mecklin JP, Moeslein G, Sampson JR, Capella G; Mallorca Group. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. *Gut*. 2017 Jul 28. doi: 10.1136/gutjnl-2017-314057.
<http://gut.bmj.com/content/early/2017/07/28/gutjnl-2017-314057.long>
3. Møller P, Seppälä T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, Lindblom A, Macrae F, Blanco I, Sijmons R, Jeffries J, Vasen H, Burn J, Nakken S, Hovig E, Rødland EA, Tharmaratnam K, de Vos Tot Nederveen Cappel WH, Hill J, Wijnen J, Jenkins M, Green K, Laloo F, Sunde L, Mints M, Bertario L, Pineda M, Navarro M, Morak M, Renkonen-Sinisalo L, Frayling IM, Plazzer JP, Pylvanainen K, Genuardi M, Mecklin JP, Möslein G, Sampson JR, Capella G; Mallorca Group (<http://mallorca-group.org>). Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. *Gut*. 2017 Sep;66(9):1657-1664. doi: 10.1136/gutjnl-2016-311403.
<http://gut.bmj.com/content/66/9/1657.long>
4. Møller P, Seppälä T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, Lindblom A, Macrae F, Blanco I, Sijmons R, Jeffries J, Vasen H, Burn J, Nakken S, Hovig E, Rødland EA, Tharmaratnam K, de Vos Tot Nederveen Cappel WH, Hill J, Wijnen J, Green K, Laloo F, Sunde L, Mints M, Bertario L, Pineda M, Navarro M, Morak M, Renkonen-Sinisalo L, Frayling IM, Plazzer JP, Pylvanainen K, Sampson JR, Capella G, Mecklin JP, Möslein G; Mallorca Group (<http://mallorca-group.eu>). Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. *Gut*. 2017 Mar;66(3):464-472. doi: 10.1136/gutjnl-2015-309675.
<http://gut.bmj.com/content/66/3/464.long>

Publications where PLSD is cited (>70)

1. Payne, S. and G. Norbury "ACGS best practice guidelines for genetic testing and diagnosis of Lynch syndrome."
2. Nguyen, K. A., et al. (2017). "Advances in the diagnosis of hereditary kidney cancer: Initial results of a multigene panel test." Cancer **123**(22): 4363-4371.
<https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.30893>
3. Ryan, N. A., et al. (2017). "Association of mismatch repair mutation with age at cancer onset in Lynch syndrome: implications for stratified surveillance strategies." JAMA Oncology **3**(12): 1702-1706.
<https://jamanetwork.com/journals/jamaoncology/fullarticle/2646791>
4. Ryan, N. A., et al. (2017). "BRCA and lynch syndrome-associated ovarian cancers behave differently." Gynecologic oncology reports **22**: 108.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705797/>
5. Møller, P., et al. (2017). "Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database." Gut.
<http://gut.bmj.com/content/early/2017/07/28/gutjn1-2017-314057.long>
6. Liu, W., et al. (2017). "Cancer risk susceptibility loci in a Swedish population." Oncotarget **8**(66): 110300.
<https://doi.org/10.18632/oncotarget.22687>
7. Adachi, M., et al. (2017). "Carcinoma of the lower uterine segment diagnosed with Lynch syndrome based on MSH6 germline mutation: A case report." Journal of Obstetrics and Gynaecology Research **43**(2): 416-420.
<https://doi.org/10.1111/jog.13202>
8. Kaul, K. L., et al. (2017). "The case for laboratory developed procedures: quality and positive impact on patient care." Academic pathology **4**: 2374289517708309.
9. Martínez, J. L. S. "Cecilia Magdalena Egoavil Rojas."
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528950/>
10. Dörner, J., et al. (2017). "Chirurgische Prävention hereditärer gastrointestinaler Tumordispositionen Preventive surgery for hereditary disposition to gastrointestinal tumors." Der Onkologe **23**(6): 446-452.
11. Takahashi, K., et al. (2017). "Clinical characteristics of Lynch-like cases collaterally classified by Lynch syndrome identification strategy using universal screening in endometrial cancer." Gynecol Oncol **147**(2): 388-395.
12. Sjöström, O., et al. (2017). "Colonoscopic surveillance—a cost-effective method to prevent hereditary and familial colorectal cancer." Scandinavian journal of gastroenterology **52**(9): 1002-1007.
<https://www.tandfonline.com/doi/full/10.1080/00365521.2017.1327615>

13. Boonstra, J. J., et al. (2017). "Colonoscopy in Lynch syndrome: the need for a new quality score." Familial cancer **16**(2): 239-241.
14. Lynch, P. M. (2018). "Colorectal cancer genetics screening in the community: are we ready? Can we do it?" Clinical Gastroenterology and Hepatology **16**(1): 21-23.
15. Rodrigues, R. V., et al. (2018). "Colorectal cancer surveillance in Portuguese families with lynch syndrome: a cohort study." International journal of colorectal disease: 1-8.
16. Taylor, A., et al. (2018). "Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group." Journal of medical genetics: jmedgenet-2017-105188.
<http://img.bmj.com/content/early/2018/04/16/jmedgenet-2017-105188.long>
17. Cenin, D. R., et al. (2018). "Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population." Journal of gastroenterology and hepatology.
<https://doi.org/10.1111/jgh.14154>
18. Forsberg, A., et al. (2017). "Defining new colorectal cancer syndromes in a population-based cohort of the disease." Anticancer research **37**(4): 1831-1835.
<http://ar.iarjournals.org/content/37/4/1831.long>
19. González-Acosta, M., et al. (2017). "Elucidating the clinical significance of two PMS2 missense variants coexisting in a family fulfilling hereditary cancer criteria." Familial cancer **16**(4): 501-507.
20. Mandelker, D. and L. Zhang (2018). "The emerging significance of secondary germline testing in cancer genomics." The Journal of pathology.
<https://doi.org/10.1002/path.5031>
21. Staff, S., et al. (2016). "Endometrial cancer risk factors among Lynch syndrome women: a retrospective cohort study." British Journal of Cancer **115**(3): 375.
<https://www.nature.com/articles/bjc2016193>
22. Schon, K., et al. (2018). "Evaluation of universal immunohistochemical screening of sebaceous neoplasms in a service setting." Clinical and experimental dermatology.
<https://doi.org/10.1111/ced.13359>
23. Chen, Y., et al. (2017). "Exploring clinicians' attitudes about using aspirin for risk reduction in people with Lynch syndrome with no personal diagnosis of colorectal cancer." Familial cancer **16**(1): 99-109.
24. Nagasaki, T., et al. (2017). "Feasibility of Segmental Colectomy Followed by Endoscopic Surveillance as a Treatment Strategy for Colorectal Cancer Patients with Lynch Syndrome." Digestive surgery.
25. Constantinou, P. and M. Tischkowitz (2017). "Genetics of gynaecological cancers." Best Practice & Research Clinical Obstetrics & Gynaecology **42**: 114-124.
26. Ohmoto, A., et al. (2018). "Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines." Journal of Gastroenterology: 1-9.

27. Kanth, P., et al. (2017). "Hereditary colorectal polyposis and cancer syndromes: A primer on diagnosis and management." The American journal of gastroenterology **112**(10): 1509.
28. Chen, E., et al. (2018). "Hereditary Nonpolyposis Colorectal Cancer and Cancer Syndromes: Recent Basic and Clinical Discoveries." Journal of Oncology **2018**.
29. Borazanci, E. and S. Haag (2017). Hereditary Pancreatic Cancer. Challenges in Pancreatic Pathology, InTech.
30. Mork, M. E., et al. (2016). "Identification of a novel PMS2 alteration c. 505C> G (R169G) in trans with a PMS2 pathogenic mutation in a patient with constitutional mismatch repair deficiency." Familial cancer **15**(4): 587-591.
31. Dominguez-Valentin, M., et al. (2018). "Identification of genetic variants for clinical management of familial colorectal tumors." Bmc Medical Genetics **19**(1): 26.
<https://bmcmolgenet.biomedcentral.com/articles/10.1186/s12881-018-0533-9>
32. Mork, M. E., et al. (2017). "Identification of MSH2 inversion of exons 1–7 in clinical evaluation of families with suspected Lynch syndrome." Familial cancer **16**(3): 357-361.
33. Chang, K., et al. (2018). "Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome." JAMA Oncology.
34. Vasen, H. F. (2017). The importance of a well-structured pancreatic screening program for familial and hereditary pancreatic cancer, Springer.
35. Phelan, A., et al. (2018). "Inherited forms of bladder cancer: a review of lynch syndrome and other inherited conditions." Future Oncology(0).
36. Chen, F., et al. (2017). "Inherited pancreatic cancer." Chinese clinical oncology **6**(6).
37. Pilozzi, E., et al. (2017). "Left-sided early onset colorectal carcinomas: A sporadic neoplasm with aggressive behavior." The American Journal of Surgery **214**(3): 421-427.
38. McMahan, R. "LYNCH SYNDROME." Editorial Board.
39. Win, A. K., et al. (2016). Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis.
40. Malik, S. S., et al. (2017). "Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis." Familial cancer: 1-8.
<https://link.springer.com/article/10.1007%2Fs10689-017-0062-2>
41. Anyla, M., et al. (2018). "Metachronous colorectal cancer risk in Lynch syndrome patients—should the endoscopic surveillance be more intensive?" International journal of colorectal disease: 1-6.
42. Kansikas, M., et al. (2001). "Mismatch Repair Genes." eLS: 1-6.
43. Dominguez-Valentin, M., et al. (2016). "MLH1 Ile219Val polymorphism in Argentinean families with suspected Lynch syndrome." Frontiers in Oncology **6**: 189.
<https://www.frontiersin.org/articles/10.3389/fonc.2016.00189/full>
44. Niskakoski, A., et al. (2018). "Molecular changes preceding endometrial and ovarian cancer: a study of consecutive endometrial specimens from Lynch syndrome surveillance." Modern Pathology: 1.
45. Snowsill, T., et al. (2017). "Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation."

46. Nguyen, A., et al. (2016). "MSI detection and its pitfalls in CMMRD syndrome in a family with a bi-allelic MLH1 mutation." Familial cancer **15**(4): 571-577.
47. Espenschied, C. R., et al. (2017). "Multigene panel testing provides a new perspective on Lynch syndrome." Journal of Clinical Oncology **35**(22): 2568-2575.
48. Lindberg, L. J., et al. (2016). "Outcome of 24 years national surveillance in different hereditary colorectal cancer subgroups leading to more individualised surveillance." Journal of medical genetics: jmedgenet-2016-104284.
<http://img.bmj.com/content/54/5/297.long>
49. Ryan, N., et al. (2017). "Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer." Gynecol Oncol **144**(3): 491-495.
[https://www.gynecologiconcology-online.net/article/S0090-8258\(17\)30042-2/fulltext](https://www.gynecologiconcology-online.net/article/S0090-8258(17)30042-2/fulltext)
50. Ma, H., et al. (2018). "Pathology and genetics of hereditary colorectal cancer." Pathology.
51. Evans, D. G., et al. (2018). "Penetrance estimates for BRCA1, BRCA2 (also applied to Lynch syndrome) based on presymptomatic testing: a new unbiased method to assess risk?" Journal of medical genetics: jmedgenet-2017-105223.
<http://img.bmj.com/content/early/2018/02/26/jmedgenet-2017-105223.long>
52. Lynch, H. T., et al. (2017). "Phenotypic and genotypic heterogeneity of Lynch syndrome: a complex diagnostic challenge." Familial cancer: 1-12.
53. Wang, T. and E. H. Fern (2017). "Prediction of New Cancer in Patients with Lynch Syndrome Based on Mutation Patterns." Research Journal of Oncology **1**(1).
54. Kast, K., et al. (2016). "Prevalence of Lynch syndrome in unselected patients with endometrial or ovarian cancer." Archives of gynecology and obstetrics **294**(6): 1299-1303.
55. Egoavil, C. (2017). "Prevalencia del Síndrome de Lynch en Pacientes con Cáncer de Endometrio no Seleccionado."
56. Имянитов, Е. (2016). "PREVENTION AND EARLY DETECTION OF HEREDITARY TUMORS."
57. Poole, E. M., et al. (2016). "Prognostic implications of reproductive and lifestyle factors in ovarian cancer." Gynecol Oncol **142**(3): 574-587.
58. Mills, K. and K. Fuh (2017). "Recent advances in understanding, diagnosing, and treating ovarian cancer." F1000Research **6**.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288682/>
59. Mills, K. and K. Fuh (2017). "Recent advances in understanding, diagnosing, and treating ovarian cancer [version 1; referees: 3 approved]."
60. Yang, J., et al. (2017). "risk of subsequent primary malignancies among patients with prior colorectal cancer: a population-based cohort study." OncoTargets and therapy **10**: 1535.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359119/>
61. Maida, M., et al. (2017). "Screening of colorectal cancer: present and future." Expert review of anticancer therapy **17**(12): 1131-1146.

62. Rossi, B. M., et al. (2017). "SINDROMES HEREDITARIOS QUE PREDISPONEN AL DESARROLLO DEL CANCER COLORRECTAL." Revista Médica Clínica Las Condes **28**(4): 617-626.
63. Carnevali, I., et al. (2017). "Somatic Testing on Gynecological Cancers Improve the Identification of Lynch Syndrome." International Journal of Gynecological Cancer **27**(7): 1543-1549.
64. Renkonen-Sinisalo, L., et al. (2017). "Subtotal Colectomy for Colon Cancer Reduces the Need for Subsequent Surgery in Lynch Syndrome." Diseases of the Colon & Rectum **60**(8): 792-799.
65. Rossi, B. M., et al. (2017). "A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America." Bmc Cancer **17**(1): 623.
<https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3599-4>
66. Coelho, H., et al. (2017). "A systematic review of test accuracy studies evaluating molecular micro-satellite instability testing for the detection of individuals with lynch syndrome." Bmc Cancer **17**(1): 836.
<https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3820-5>
67. Ahadova, A., et al. (2018). "Three molecular pathways model colorectal carcinogenesis in Lynch syndrome." International journal of cancer.
68. Therkildsen, C., et al. (2017). "Towards gene-and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types." British Journal of Cancer **117**(11): 1702.
69. Tawana, K., et al. (2018). "Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?" Leukemia: 1.
70. Clark, S. (2017). "Universal testing of colorectal cancer for deficient mismatch repair-a new era has arrived." Colorectal Disease **19**(9): 801-802.
71. Da Silva, F. C., et al. (2016). "Update on hereditary colorectal cancer." Anticancer research **36**(9): 4399-4405.
<http://ar.iijournals.org/content/36/9/4399.long>
72. Seppälä, T. T., et al. (2017). "Uptake of genetic testing by the children of Lynch syndrome variant carriers across three generations." European Journal of Human Genetics **25**(11): 1237.
<https://www.nature.com/articles/ejhg2017132>
73. Hansen, M. F., et al. (2017). "Use of multigene-panel identifies pathogenic variants in several CRC-predisposing genes in patients previously tested for Lynch Syndrome." Clinical Genetics **92**(4): 405-414.
<https://onlinelibrary.wiley.com/doi/full/10.1111/cge.12994>
74. Ladigan, S., et al. (2017). Verbundprojekt „Familiärer Darmkrebs“. Forum, Springer.
75. Valo, S. (2016). "Western diet and genetic predisposition as risk factors of colon cancer."

76. Miller, G. C., et al. (2018). "Yield of Universal Testing for DNA Mismatch Repair Protein Deficiency in Colorectal Carcinoma From an Australian Community-based Practice." [bioRxiv: 270322](https://doi.org/10.1101/270322).

Social media and others

<https://twitter.com/Lynchsyndromirl/status/915198635889045506>

<https://bestprac.no/dokumentert-effekt-av-tiltak-mot-arvelig-tarmkreft-prospective-lynch-syndrome-database-plsd/>

<https://www.practiceupdate.com/content/lynch-syndrome-cancer-risk-and-survival-by-genotype/56462>

<https://www.jwatch.org/na39980/2015/12/23/cancer-incidence-and-survival-during-surveillance-lynch>

<https://www.youtube.com/watch?v=HlaNc6f5uuQ&t=1s>

<https://www.ambrygen.com/file/view/1090/Lynch%20Research%20Summary%20JCO%20FINAL.pdf>